Ibio, Common Stock Stock Today
| IBIO Stock | USD 5.08 0.05 0.97% |
PerformanceSolid
| Odds Of DistressQuite High
|
IBio, Common is selling at 5.08 as of the 16th of March 2025; that is 0.97 percent decrease since the beginning of the trading day. The stock's open price was 5.13. IBio, Common has more than 61 % chance of experiencing financial distress in the next few years of operation. However, it had a very solid returns during the last 90 days. The performance scores are derived for the period starting the 16th of December 2024 and ending today, the 16th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 19th of August 2008 | Category Healthcare | Classification Health Care |
iBio, Inc., a biotechnology company, provides contract development and manufacturing services to collaborators and third-party customers in the United States. The company was incorporated in 2008 and is headquartered in Bryan, Texas. Ibio operates under Biotechnology classification in the United States and is traded on AMEX Exchange. The company has 9.14 M outstanding shares of which 307.8 K shares are currently shorted by private and institutional investors with about 1.46 trading days to cover. More on iBio, Common Stock
Moving against IBio, Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
IBio, Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| Executive Chairman and CEO | Robert Kay | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thematic Ideas | (View all Themes) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Management, Biotech, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Average Analyst Recommendation | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Financial Strength
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Debt LevelsIBio, Common can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand IBio, Common's financial leverage. It provides some insight into what part of IBio, Common's total assets is financed by creditors.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
iBio, Common Stock (IBIO) is traded on NYSE MKT Exchange in USA. It is located in 11750 Sorrento Valley Road, San Diego, CA, United States, 92121 and employs 16 people. IBio, Common is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Micro-Cap' category with a current market capitalization of 23.3 M. iBio, Common Stock conducts business under Biotechnology sector and is part of Health Care industry. The entity has 9.14 M outstanding shares of which 307.8 K shares are currently shorted by private and institutional investors with about 1.46 trading days to cover.
iBio, Common Stock currently holds about 33.52 M in cash with (18.55 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.72.
Check IBio, Common Probability Of Bankruptcy
Ownership AllocationThe market capitalization of IBio, Common is $23.3 Million. 30% of iBio, Common Stock outstanding shares are owned by outside corporations. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Accordingly, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Note, that even with negative profits, if the true value of the entity is larger than the current market value, you may still be able to generate positive returns on investment in this company.
Check IBio, Ownership Details
IBio, Common Historical Income Statement
IBio, Stock Against Markets
IBio, Common Corporate Management
| Lisa Middlebrook | Chief Officer | Profile | |
| Stephen Kilmer | Investor Officer | Profile | |
| Marc JD | General Counsel | Profile | |
| Melissa Berquist | VP Health | Profile | |
| Robert Lutz | Chief Officer | Profile | |
| Dr DVM | Chief Officer | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iBio, Common Stock. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Portfolio Diagnostics module to use generated alerts and portfolio events aggregator to diagnose current holdings.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of IBio, Common. If investors know IBio, will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about IBio, Common listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share | Quarterly Revenue Growth (0.88) | Return On Assets | Return On Equity |
The market value of iBio, Common Stock is measured differently than its book value, which is the value of IBio, that is recorded on the company's balance sheet. Investors also form their own opinion of IBio, Common's value that differs from its market value or its book value, called intrinsic value, which is IBio, Common's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IBio, Common's market value can be influenced by many factors that don't directly affect IBio, Common's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IBio, Common's value and its price as these two are different measures arrived at by different means. Investors typically determine if IBio, Common is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IBio, Common's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.